Candesartan + Placebo
Phase 3Completed 0 watching 0 views this weekπ Rising
77
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Congestive Heart Failure
Conditions
Congestive Heart Failure
Trial Timeline
Jun 1, 1999 β May 1, 2003
NCT ID
NCT00634712About Candesartan + Placebo
Candesartan + Placebo is a phase 3 stage product being developed by AstraZeneca for Congestive Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00634712. Target conditions include Congestive Heart Failure.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00699452 | Phase 3 | UNKNOWN |
| NCT00319202 | Approved | Terminated |
| NCT00328302 | Approved | UNKNOWN |
| NCT00634712 | Phase 3 | Completed |
| NCT00634309 | Phase 3 | Completed |
| NCT00634400 | Phase 3 | Completed |
Competing Products
20 competing products in Congestive Heart Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + Placebo | AstraZeneca | Phase 3 | 77 |
| AC2592 + placebo | AstraZeneca | Phase 2 | 52 |
| Dapagliflozin + Placebo | AstraZeneca | Approved | 85 |
| Enoximone + Metoprolol succinate + Placebo to match enoximone + Placebo to match metoprolol succinate | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| KW-3902IV | Merck | Phase 2 | 52 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| KW-3902IV | Merck | Phase 2 | 52 |
| Sitagliptin | Merck | Phase 1 | 33 |
| Low Dose Bisoprolol + High Dose Bisoprolol | Merck | Approved | 85 |
| rolofyline + Comparator Placebo (unspecified) | Merck | Phase 2 | 52 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| vildagliptin + placebo of vildagliptin | Novartis | Approved | 85 |
| Relaxin + Placebo | Novartis | Phase 2/3 | 65 |
| Relaxin | Novartis | Phase 2 | 52 |